Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 495

1.

Clinical aspects of percutaneous transluminal angioplasty for autogenous arteriovenous fistula dysfunction: An early period experience.

Lee JS, Kim JH, Park SC, Kim SD.

Asian J Surg. 2020 Jan 12. pii: S1015-9584(19)30863-2. doi: 10.1016/j.asjsur.2019.11.018. [Epub ahead of print]

PMID:
31941592
2.

Delayed type Ib endoleak leading to impending rupture of abdominal aorta after endovascular abdominal aortic aneurysm repair (EVAR).

Park SC, Lee WR, Lee JS, Kim SD.

Asian J Surg. 2020 Jan 10. pii: S1015-9584(19)30865-6. doi: 10.1016/j.asjsur.2019.11.020. [Epub ahead of print] No abstract available.

PMID:
31932153
3.

Do junctional neural tube defect and segmental spinal dysgenesis have the same pathoembryological background?

Wang KC, Lee JS, Kim K, Im YJ, Park K, Kim KH, Phi JH, Kim SK, Lee JY.

Childs Nerv Syst. 2019 Dec 10. doi: 10.1007/s00381-019-04425-4. [Epub ahead of print]

PMID:
31823069
4.

Central hemodynamic characteristics of young adults with isolated systolic hypertension: an ambulatory blood pressure monitoring-based study of real-world clinical patients.

Kim S, Lee JS, Kim W, Kim YH, Kim JS, Lim SY, Kim SH, Ahn JC, Park CG, Song WH.

Hypertens Res. 2019 Dec 6. doi: 10.1038/s41440-019-0352-1. [Epub ahead of print]

PMID:
31811243
5.

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.

J Clin Oncol. 2019 Dec 6:JCO1900457. doi: 10.1200/JCO.19.00457. [Epub ahead of print]

PMID:
31809241
6.

Development of Human Serum Albumin Selective Fluorescent Probe Using Thieno[3,2-b]pyridine-5(4H)-one Fluorophore Derivatives.

Lee S, Sung DB, Kang S, Parameswaran S, Choi JH, Lee JS, Han MS.

Sensors (Basel). 2019 Dec 1;19(23). pii: E5298. doi: 10.3390/s19235298.

7.

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.

Kwon JH, Kim KJ, Sung JH, Suh KJ, Lee JY, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Kim S, Yoon SS, Lee JS.

Cells. 2019 Nov 28;8(12). pii: E1538. doi: 10.3390/cells8121538.

8.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators.

N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.

PMID:
31751012
9.

Sensitivity of Various Evaluating Modalities for Predicting a Pathologic Complete Response After Preoperative Chemoradiation Therapy for Locally Advanced Rectal Cancer.

Jung S, Parajuli A, Yu CS, Park SH, Lee JS, Kim AY, Lee JL, Kim CW, Yoon YS, Park IJ, Lim SB, Kim JC.

Ann Coloproctol. 2019 Oct;35(5):275-281. doi: 10.3393/ac.2019.01.07. Epub 2019 Oct 31.

10.

Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards.

Choi Y, Kim JW, Suh KJ, Lim YJ, Lee JY, Kang BD, Kim JW, Kim SH, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS.

BMC Palliat Care. 2019 Nov 4;18(1):93. doi: 10.1186/s12904-019-0477-7.

11.

Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.

Keam B, Kang CK, Jun KI, Moon SM, Suh KJ, Lee DW, Ock CY, Kim M, Choi Y, Lim Y, Lee KH, Kim SH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Lee JS, Kim ES, Kim HB, Kim NJ, Kim YJ, Park WB, Oh MD.

Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print]

PMID:
31680143
12.

Chemoradiotherapy versus radiotherapy alone following induction chemotherapy for elderly patients with stage III lung cancer.

Kim DY, Song C, Kim SH, Kim YJ, Lee JS, Kim JS.

Radiat Oncol J. 2019 Sep;37(3):176-184. doi: 10.3857/roj.2019.00087. Epub 2019 Sep 30.

13.

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators.

Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.

PMID:
31590988
14.

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC.

Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3.

PMID:
31587882
15.

Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.

Cho BC, Kim DW, Park K, Lee JS, Yoo SS, Kang JH, Lee SY, Kim CH, Jang SH, Kim YC, Yoon HK, Han JY, Kim SW.

Curr Med Res Opin. 2019 Oct 4:1. doi: 10.1080/03007995.2019.1676708. [Epub ahead of print]

PMID:
31581843
16.

Untargeted Metabolomics Toward Systematic Characterization of Antioxidant Compounds in Betulaceae Family Plant Extracts.

Lee S, Oh DG, Singh D, Lee HJ, Kim GR, Lee S, Lee JS, Lee CH.

Metabolites. 2019 Sep 16;9(9). pii: E186. doi: 10.3390/metabo9090186.

17.

Correction to "Streptoglycerides A-D with a Rare 6/5/5 Tricyclic Ring Skeleton from a Marine Actinomycete Streptomyces species".

Choi BK, Park SY, Choi DK, Shin B, Shin YH, Oh DC, Lee HS, Lee HS, Lee YJ, Lee JS, Lee JH, Shin HJ.

Org Lett. 2019 Oct 4;21(19):8144. doi: 10.1021/acs.orglett.9b03059. Epub 2019 Sep 13. No abstract available.

PMID:
31515998
18.

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

Heo JY, Park C, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Kim SH, Kim YJ, Lee JS, Heo DS.

Thorac Cancer. 2019 Nov;10(11):2117-2123. doi: 10.1111/1759-7714.13195. Epub 2019 Sep 11.

19.

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.

Kim YJ, Keam B, Ock CY, Song S, Kim M, Kim SH, Kim KH, Kim JS, Kim TM, Kim DW, Lee JS, Heo DS.

Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.

PMID:
31494530
20.

Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation.

Lee JS, Park SY, Kim NY, Kim DW, Oh JE, Heo E, Lee JS, Yoo YC.

J Clin Med. 2019 Sep 3;8(9). pii: E1380. doi: 10.3390/jcm8091380.

Supplemental Content

Loading ...
Support Center